Table 1.
Summary of studies reported beneficial of RRF on mortality
| Reference (year) | Study design | Number, characteristics and modality of subjects | Measurement of RRF | RR or OR of mortality per increase of RRF (CI or P-value) |
|---|---|---|---|---|
| Maiorca et al. (1995) [4] | 3-year prospective single centre | Prevalent 68 CAPD and 34 HD | GFR 10 L/week/1.73 m2 | 0.4 (P < 0.001) |
| Diaz-Buxo et al. (1999) [5] | 1-year prospective single centre | Prevalent 2686 CAPD or CCPD | Renal CrCl 10 L/week/1.73 m2 | 0.89 (P = 0.003) |
| Rocco et al. (2000) [6] | 7-month prospective multicentre | Prevalent 1446 CAPD or CCPD | Renal CrCl 10 L/week/1.73 m2 | 0.6 (0.4–0.8) |
| Szeto et al. (2000) [10] | 3-year prospective single centre | Prevalent 270 CAPD | GFR 1 mL/min/1.73 m2 | 0.65 (0.45–0.94) |
| Ates et al. (2001) [11] | 3-year prospective single centre | Incident 125 CAPD | GFR 1 mL/min/1.73 m2 | 0.53 (0.31–0.92) |
| Bargman et al. (2001) [12] | 2-year prospective multicentre | Prevalent 680 CAPD | GFR 5 L/week/1.73 m2 Urine volume > 250 mL/day |
0.88 (0.83–0.94) 0.64 (0.51–0.8) |
| Paniagua et al. (2002) [13] | 2-year multicentre randomized controlled | Incident 965 CAPD | Renal CrCl 10 L/week/1.73 m2 Renal Kt/V 0.1 unit |
0.89 (P = 0.01) 0.94 (P = 0.01) |
| Termorshuizen et al. (2003) [14] | 3-year prospective multicentre | Incident 413 CAPD | GFR 1 mL/min/1.73 m2 | 0.88 (0.79–0.99) |
| Chung et al. (2003) [15] | 2-year retrospective | Incident 117 CAPD | GFR 1 mL/min/1.73 m2 | 0.79 (0.62–0.99) |
| Szeto et al. (2004) [3] | 5-year prospective single centre | Prevalent 270 CAPD | GFR 1 mL/min/1.73 m2 | 0.8 (0.73–0.88) |
| Rumpsfeld et al. (2009) [16] | 3-year retrospective | Incident 2434 CAPD or APD | GFR 10 L/week/1.73 m2 | 0.93 (P = 0.01) |